Anti-tumor necrosis factor therapy for inflammatory bowel disease in the setting of immunosuppression for solid organ transplantation

American Journal of Gastroenterology

Volumn 105, Issue 5, 2010, Pages 1210-1211

  El Nachef, Najwa ^a   Terdiman, Jonathan ^a   Mahadevan, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; INFLIXIMAB; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; AGED; ARTHRITIS; CASE REPORT; CROHN DISEASE; ENTERITIS; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LETTER; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT FAILURE;

ADULT; AGED; BIOLOGICAL PRODUCTS; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MIDDLE AGED; ORGAN TRANSPLANTATION; RISK ASSESSMENT; SAMPLING STUDIES; TRANSPLANTATION IMMUNOLOGY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951965361     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.33     Document Type: Letter

References (12)

1. Hampton DD, Poleski MH, Onken JE. Infl ammatory bowel disease following solid organ transplantation. Clin Immunol 2008; 128: 287-293
2. Worns MA, Lohse AW, Neurath MF et al. Five cases of de novo infl ammatory bowel disease aft er orthotopic liver transplantation. Am J Gastroenterol 2006; 101: 1931-1937
3. Riley TR, Schoen RE, Lee RG et al. A case series of transplant recipients who despite immunosuppression developed infl ammatory bowel disease. Am J Gastroenterol 1997; 92: 279-282
4. Verdonk RC, Dijkstra G, Haagsma EB et al. Infl ammatory bowel disease aft er liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006; 6: 1422-1429
5. Paptheodoridis GV, Hamilton M, Mistry PK et al. Ulcerative colitis has an aggressive course aft er orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-644
6. American Gastroenterological Association. Consensus development conference on the use of biologics in the treatment of infl ammatory bowel disease, June 21-23, 2006. Gastroenterology 2007; 133: 312-339
7. Toruner M, Loft us EV, Harmsen WS et al. Risk factors for opportunistic infections in patients with infl ammatory bowel disease. Gastroenterology 2008; 134: 929-936
8. Maser EA, Deconda D, Lichtiger S et al. Cyclosporine and infl iximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6: 1112-1116
9. Kandiel A, Fraser AG, Korelitz BI et al. Increased risk of lymphoma among infl ammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54: 1121-1125
10. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful eff ects in randomized controlled trials. JAMA 2006; 295: 2275-2285
11. Nalensnik MA, Jaff e R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173-192
12. Taylor AL, Marcus R, Bradley A. Post-transplant lymphoproliferative disorders aft er solid organ transplant. Crit Rev Oncol Hematol 2005; 56: 155-167